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Restricted mobility of specific 
functional groups reduces anti-
cancer drug activity in healthy cells
Murillo L. Martins1,2, Rosanna Ignazzi1, Juergen Eckert3,4, Benjamin Watts5, Ramon Kaneno2, 
Willian F. Zambuzzi2, Luke Daemen4, Margarida J. Saeki2 & Heloisa N. Bordallo1,6
The most common cancer treatments currently available are radio- and chemo-therapy. These therapies 
have, however, drawbacks, such as, the reduction in quality of life and the low efficiency of radiotherapy 
in cases of multiple metastases. To lessen these effects, we have encapsulated an anti-cancer drug into a 
biocompatible matrix. In-vitro assays indicate that this bio-nanocomposite is able to interact and cause 
morphological changes in cancer cells. Meanwhile, no alterations were observed in monocytes and 
fibroblasts, indicating that this system might carry the drug in living organisms with reduced clearance 
rate and toxicity. X-rays and neutrons were used to investigate the carrier structure, as well as to assess 
the drug mobility within the bio-nanocomposite. From these unique data we show that partial mobility 
restriction of active groups of the drug molecule suggests why this carrier design is potentially safer to 
healthy cells.
Cancer is one of the main worldwide public health concerns. In Europe, the incidence of this disease has increased 
from 3.2 million new cases in 2008 to 3.45 million in 2012, with a mortality rate around 50%1,2. Paclitaxel (PTX) 
is one of the most effective drugs currently available for the treatment of breast, lung and ovarian cancers3–6. Its 
function is based on a unique mechanism involving the stabilization of cell microtubules, which explains its 
therapeutic success7. However, considerable limitations still exist regarding this drug, mainly due to its low water 
solubility (~0.4 μg/mL) and, of course, its toxicity to healthy cells. To increase its solubility, a drug is often formu-
lated in organic solvents, such as dehydrated ethanol and polyoxyethylated castor oil. Unfortunately this approach 
causes many side effects, such as hypersensitivity reactions and hyperlipidaemia8.
Consequently the development or modification of systems for accommodating and delivering anti-cancer 
drugs is of utmost importance9. A promising alternative is the use of soluble polymeric nano-carriers for con-
trolling the pharmacokinetic and bio-distribution of the drug10. The biopolymer chitosan, in particular, has 
attracted great interest in biomedical applications because of its biocompatibility and biodegradability11. This 
path has also been used as an encapsulation matrix for PTX with promising results12,13. Further improvements 
can be made by modifying the surface features of the drug delivery system with low toxicity compounds, 
which may also make possible to increase the adhesion of the carrier to cancer cells14. To this end, the use of 
hydroxyapatite (Ca10(PO4)6(OH)2, hereafter HAP), the main inorganic constituent of human bones and teeth, is 
an excellent candidate. At the nano-scale, HAP presents special biocompatibility as well as non-immunogenicity, 
non-inflammatory behaviour, high osteoconductivity and good adhesion to different types of cancer cells15,16. Of 
even more interest, HAP nanoparticles (nHAP) show inhibitory effect on cancer cells proliferation with lower 
effects on the healthy ones16–19. Consequently, the combination of the properties of nHAP with biopolymers in 
a nano-composite, may lead to drug delivery systems with inherent effects on cancer cells. However, to take full 
advantage of the nHAP properties, these nanoparticles must be in the out layer of the composite20. Additionally 
to the benefits derived from combining a biopolymer with nHAP, inclusion of a drug into nano-carriers with 
magnetic properties, for instance Mn-Zn ferrite nanoparticles, offers remarkable new possibilities. For exam-
ple, guiding the drug carrier along the body using external magnetic field as well as monitoring its position by 
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gradiometers or magnetic resonance imaging21–24. Finally, magnetic hyperthermia treatments, which represent a 
promising technique used in combination with radio and chemotherapy, also become practicable25–27.
Following the ideas described above, we have encapsulated PTX into a bio-nanocomposite (hereafter bio-NCP 
and bio-NCP + PTX) formed by Mn-Zn ferrite nanoparticles coated with chitosan, which surface was modified 
with nHAP28.
Morphological in-vitro tests, performed using scanning electron microscopy (SEM) and energy dispersive 
X-ray spectroscopy (EDS), based on a methodology developed by our group, allowed for a preliminary insight 
on the interaction between cells and nanoparticles without the need of fluorescent or radioactive markers in 
the nanoparticles. The results suggested that normal monocytes and two distinct types of tumour cells interact 
differently with the bio-NCP. While no toxicity was observed on the healthy cells, morphological changes were 
detected mainly in colon cancer cells.
The rather challenging characterization of the formulated bio-NCP + PTX and insight into the dynamics of 
the encapsulated and released drug were achieved by using advanced microscopy and spectroscopy techniques, 
respectively. These include near edge X-ray absorption fine structure (NEXAFS) spectroscopy, scanning trans-
mission X-ray microscopy (STXM) and inelastic neutron scattering (INS).
NEXAFS made possible to characterize different organic groups on account of the interaction of X-rays 
with the K-shell of the carbon atoms, without the magnetic nanoparticles affecting the result29. By combining 
NEXAFS with STXM, the chemical compositional map along with the visual analysis of the PTX distribution of 
the bio-NCP was obtained. These results indicate that PTX is distributed within the polymeric part of the carrier.
Finally, the comparison of the dynamics of the encapsulated drug to that of the pure form–a key step in under-
standing and controlling the polymer/drug interactions and one of the major questions in the further develop-
ment of this technology towards clinical trials–was obtained by combining INS with Density Functional Theory 
(DFT) calculations. These results provided for the assignment of the vibrational modes, including those observed 
within the drug carrier30–32. Using this approach, we show that although the phenyl and acetyl vibrational modes 
are constrained by the encapsulation, they seem to be recovered after the drug release. This is important because 
the PTX activity is known to be related to the mobility of these groups7.
To conclude, the ensemble of our results indicates that the proposed bio-NCP can open new opportunities for 
the emerging field of drug delivery.
Results
Monocytes reaction inhibited by the hydroxyapatite modification. The potential of the bio-NCP 
as a PTX carrier is highlighted by the in-vitro tests with monocytes, which tend to promote phagocytosis in for-
eign particles or molecules in the human body, blocking them to reach target tissues.
Morphological changes of monocytes from a healthy donor (control group) (Fig. 1(a)) were visually evaluated 
in response to their contact for 2 h with the pure ferrite nanoparticles (Fig. 1(b)) and with the bio-NCP (Fig. 1(c)) 
by means of SEM. In both cases, considerable morphological changes were not observed. Subsequently, the cells 
were analysed by EDS in order to determine regions with high Fe concentration, the main component of the 
Mn-Zn ferrite nanoparticles that composes the core of the bio-NCP. Such observation provides insight on the 
interactions between the cells and the nanoparticles. This is indeed the case in the assay with Mn-Zn ferrite, 
where cells with high Fe concentration, marked green and highlighted by the arrows in the representative SEM 
micrograph, were observed as shown in Fig. 1(b). This scenario changes by modifying the nanoparticles with the 
bio-NCP, where the cells present smaller Fe concentration after the assay as shown in Fig. 1(c). Thus suggesting 
that the bio-polymeric coating modified with nHAP inhibits the reaction from the defence cells, which is known 
to compromise the function of the carrier33.
Morphological changes observed on cancer cell lines and cytotoxicity tests in fibroblasts. 
Figure 2(a) presents representative SEM images of control groups of colon (top) and lung (bottom) cancer cells, 
while Fig. 2(b,c) present the cells after 2 h contact with Mn-Zn ferrite and bio-NCP nanoparticles, respectively. 
Figure 1. Representative SEM images and EDS analyses of normal monocytes of a healthy donor (control 
group) (a) and the cells after being in contact for 2 h either with Mn-Zn ferrite nanoparticles (b) or with the bio-
NCP (c). High Fe concentrations, marked green, suggest uptake from the Mn-Zn ferrite nanoparticles.
www.nature.com/scientificreports/
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The cells were also subjected to EDS analyses as depicted by the green spots, which are more evident for the cells 
tested with pure Mn-Zn ferrite nanoparticles, Fig. 2(b).
Additionally, in each figure the insets show zoomed images of selected areas to highlight cellular morpholog-
ical changes. These changes were evaluated by comparing the distribution of the cells aspect ratio, which refers to 
the ratio between the major and minor axis of an ellipse describing the shape of each cell, before and after their 
contact with the Mn-Zn ferrite and the bio-NCP nanoparticles. Under these lines, aspect ratio distributions closer 
to 1 indicate cells with predominantly spherical shapes. These results are shown in Fig. 3. From these analyses 
one obtains a mean aspect ratios of 1.9 and 1.5 for the colon and lung control groups, respectively. Interestingly, 
after contact between the colon cancer cells and both Mn-Zn ferrite and the bio-NCP the distribution of the cells 
aspect ratio showed a decrease of about 26%, reaching a mean value of 1.4. No detectable changes are detected 
for the lung cells.
Finally, a preliminary cytotoxicity test of the materials, including the bio-NCP + PTX, to healthy cells was pro-
vided by in-vitro assays with fibroblasts, adopted here as a model for healthy cells, following the recommendation 
Figure 2. Representative SEM images and EDS analyses of in-vitro analyses of colon (HCT116) and lung (3LL) 
cancer cells (control) (a) and the cells after 2 h contact with Mn-Zn ferrite (b) and bio-NCP (c). The green spots 
depict regions with high Fe concentration as determined by EDS and the insets present zoomed images of the 
selected regions. The colon cancer cells present the most evident morphological changes after contact with both 
Mn-Zn ferrite and the bio-NCP.
Figure 3. Aspect ratio distributions represented by bars for (a) colon (HCT116) and lung (3LL) cancer control 
cells and for the cells after 2 h contact with (b) Mn-Zn ferrite and (c) bio-NCP. The morphological changes, 
more evident in the colon cancer cells after contact with both Mn-Zn ferrite and the bio-NCP, are reflected by 
the sharper distributions. In each figure the symbols represent the cumulative frequency of the aspect-ratios.
www.nature.com/scientificreports/
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given by ISO 10 993-5. As presented in Fig. 4, the fibroblasts viability after the assays exhibits no significant differ-
ence in comparison with the results obtained for the control group, indicating no significant toxicity.
Chemical compositional map of the drug carrier and confirmation of successful encapsulation 
of the drug. NEXAFS spectra for PTX and bio-NCP, presented in Fig. 5(a), are broadened by the convolution 
of excitations on account of the considerable flexibility of the carbon bonds34. Nonetheless, the PTX fingerprint 
at 283.3 eV is clearly detected and can be related to a C-C π *-bond, which is characteristic of aromatic rings. A 
peak at 286 eV in the spectrum of bio-NCP may be related to a C1s → σ * transition on the C-OH bonds, while 
the broad band at 291 eV is assigned to the excitation of C, H and N bonds from the cross-linked chitosan34. The 
noteworthy peak in the bio-NCP spectrum at 347 eV is related to the Ca L3,2-edge and indicates the apatite mod-
ification on the chitosan surface35.
Figure 5(b) presents the chemical composition map derived from the STXM data. In this map the PTX is rep-
resented by yellow and the bio-NCP by red. The blue colour represents the background materials, including the 
magnetic nanoparticles. The green spots, a mixture of yellow and blue, denote regions with low PTX concentra-
tion. The resulting image shows that the drug is distributed along the chitosan/nHAP shell with the Mn-Zn ferrite 
magnetic nanoparticles forming the core of the bio-nanocomposite. This distribution confirms the successful 
encapsulation of the drug.
Initial studies of the releasing process. To verify the recovery of PTX after exposure of the 
bio-NCP + PTX in aqueous media for longer times, the latter was dispersed in water at 37 °C (human body tem-
perature) for 7 days, dried at room temperature under vacuum and investigated by FTIR. All spectral features 
Figure 4. Viability test on fibroblast after 24 h in contact with the Mn-Zn ferrite nanoparticles, the bio-
NCP and the complex bio-NCP + PTX showing no significant toxicity. Note that the control sample is the 
fibroblast without contact with any material.
Figure 5. NEXAFS spectra for PTX and the bio-NCP (a). The PTX spectrum shows a characteristic peak at 
283 eV, while the bio-NCP spectrum shows characteristic transitions at 286 eV, 291 eV and 347 eV. In (b), the 
map of the chemical composition of the bio-NCP + PTX obtained by STXM after performing singular value 
decomposition on images collected using X-rays with the following energies: 275 eV, 283 eV, 286 eV, 300 eV, 
320 eV and 347 eV. The PTX is represented in yellow, the bio-NCP in red and the blue colour corresponds to 
background materials, including the magnetic nanoparticles. The green spots denote regions with low PTX 
concentration. The compositional map shows the distribution of the PTX in the polymeric nHAP shell.
www.nature.com/scientificreports/
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specific to the dispersed sample, bio-NCP + PTX as prepared and for the pure PTX are compared to the results 
of the DFT calculations for the gas phase molecule and discussed in detail in the supplementary information. The 
most striking result was the observation of the modes located at 1535 and 1550 cm−1, assigned to benzene rings. 
These modes are recovered after the drug release and related to the anti-tumour activity of PTX7.
Insights on the interactions of the drug with its carrier. The next key point for elucidating the releas-
ing process was the analysis of the interactions of the drug with its carrier. This step was accomplished by combin-
ing INS experiments with DFT calculations on the free molecule. Details on these calculations, assisted with the 
full identification of the vibrational features in the spectra by animations for the pure and encapsulated drug are 
given in the supplementary information. It is worth noticing that the calculations are performed in the harmonic 
approximation, while the vibrational modes of our materials, particularly the low frequencies ones, are likely to 
be anharmonic modes. The schematic structure of the PTX molecule adapted from7 is also depicted in the sup-
plementary information.
In Fig. 6(a), the sharp maximum around 56 cm−1 is related to the acoustic mode for H2O36. Here we should 
recall that the PTX used in this work is a mixture of hydrated and dehydrated forms37. The modes above 60 cm−1 
are assigned to acetyl and phenyl groups in the PTX molecule are not detected in the (bio-NCP + PTX-bio-NCP) 
spectrum, which corresponds to that of the encapsulated PTX molecule. This indicates that either the molecule 
is severely constrained or has adapted a new conformation. However, it is also clear, as showed by arrows, that 
some higher frequencies vibrations assigned to the PTX molecule do remain in the (bio-NCP + PTX-bio-NCP) 
spectrum. These vibrations originate mainly from carbons in the terpene ring itself as well as from lattice motions, 
implying that the rigid structure of PTX is maintained even after encapsulation. As shown in Fig. 6(b), remaining 
methyl vibrations are also detected between 200 cm−1 and 270 cm−1, while the modes above 300 cm−1 appear 
weak on account of poor statistics from the subtraction procedure. Therefore we are led to conclude that the 
restraining of the acetyl and phenyl groups is most likely due to the folding of the molecule.
Discussion
Our first in-vitro assays show that no morphological changes were observed in monocytes after their contact 
with the pure Mn-Zn ferrite nanoparticles or with the bio-NCP. After contact with the Mn-Zn ferrite, how-
ever, several monocytes presented high Fe concentration. The latter observation indicates interaction and/or 
uptake of the magnetic nanoparticles by the monocytes. Meanwhile, very low Fe concentration was detected in 
the tests performed with the bio-NCP, which could be, in principle a consequence of the lower Fe concentra-
tion in comparison to the pure ferrite. However, given the set up of this experiment, described in the Methods 
Section, it is plausible to consider that the bio-NCP inhibits the interaction/uptake of the monocytes. Further 
in-vitro assays performed with colon and lung cancer cells indicate that both the Mn-Zn ferrite nanoparticles 
and the bio-NCP interact and cause morphological changes in cancer cells, especially those from the colon. This 
assumption is drawn based on the variation of the aspect ratio distribution, which was initially characteristic 
of elongated cells, and became closer to that describing spherical ones after the interaction. Even in an early 
stage, this is an encouraging result, since the invasiveness of colon cancer cell lines has been associated with its 
elongated morphology38. Additionally, as the response observed for both Mn-Zn ferrite nanoparticles and the 
bio-NCP are very similar, it is reasonable to hypothesize that the bio-NCP effect has its origin on the magnetic 
core. Indeed, effects of Fe-based nanoparticles on cancer cells, including those from the colon, have been attrib-
uted to controlled Fe-catalyzed reactive oxygen species (ROS) that potentially trigger autophagy and associated 
Figure 6. INS data collected at FDS between (a) 20 and 200 cm−1 and (b) between 200 and 500 cm−1. In  
(a,b) the black curve shows the PTX data, while the contribution from the encapsulated drug, shown in yellow, 
is depicted by the difference spectrum between the (bio-NCP + PTX) and (bio-NCP) spectra. The bio-NCP 
data is not shown. INS spectra obtained by DFT calculations for the free molecule are shown in green. In the 
difference spectrum, the modes assigned to acetyl and phenyl groups, observed below 80 cm−1, are not detected, 
while vibrations from the terpene ring, indicated by arrows, remain visible in the encapsulated drug. This 
indicates that the mobility of the biologically active groups of PTX is highly constrained.
www.nature.com/scientificreports/
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cell death39,40. Consequently, this observation seems to suggest that Fe ions are released through the bio-NCP’s 
polymer/apatite shell during this particular experiment. On the other hand, the lack of toxicity to fibroblasts can 
be related to the reduction of Fe toxicity to healthy cells at low Fe concentrations41,42. These are motivating results 
for the application of the bio-NCP + PTX in cancer treatment, since it seems to be non-toxic to healthy cells. 
However, these results also suggest that the drug is either in a very low concentration into the nanocomposite or 
it is not readily released under the experimental conditions of the chosen protocol. To answer this question it is 
necessary to investigate the PTX concentration into the bio-NCP. A task not at all straightforward due to the com-
plexity of the bio-NCP + PTX, which makes the application of the most common techniques, such as HPLC (high 
performance liquid chromatography), challenging and creates the need to use more sophisticated solid-state 
approaches. Therefore, by combining NEXAFS and STXM a map of the chemical composition was obtained for 
the bio-NCP + PTX. This map shows that a significant amount of the drug is indeed distributed within the chi-
tosan and the nHAP shell, suggesting that the slow PTX release is most likely due to its confinement in the matrix.
The latter observation pointed us to the need of understanding how the confinement influences the PTX 
dynamics. This question was answered by combining INS and DFT. The simplicity of the neutron− nucleus inter-
action and the exceptionally high incoherent scattering cross-section of the hydrogen atom compared to that of 
any other element were key to such understanding43. From such analysis we concluded that the mobility of the 
biologically active groups of PTX, i.e. acetyl and phenyl groups, are highly constrained in the bio-NCP + PTX. 
Therefore, one can hypothesize that the carrier limits the PTX’s activity not only as a physical barrier between the 
drug and the action sites, but also by restricting motions on specific parts of the molecule. However, after release, 
these vibrational motions were partially recovered, as observed by means of FTIR, indicating that the anti-cancer 
agent might regain its active form.
From the viability and INS results it is now clear that before envisaging future applications of the 
bio-NCP + PTX in in-vivo trials, the drug release rate needs to be better controlled. One obvious approach to 
circumvent the problem would be the modification of the bio-NCP structure, i.e the cross-linking and mimetiza-
tion degree over the chitosan, or even the choice of another polymer with a different surface charge distribution, 
such as poly-ethylene glycol44. Nonetheless before progressing in this direction, few questions need to be further 
considered, such as the evaluation of the release behavior of PTX from the bio-NCP in the surroundings of cancer 
cells. The inherent slightly lower pH environment compared to that of healthy cells could be enough to degrade 
or relax the chitosan network45,46. In addition, the use of radiofrequency as another possibility ought to be investi-
gated. In this case, by heating the magnetic nanoparticles27 the polymeric network can be relaxed and in turn the 
drug release could be facilitated.
In conclusion, we report on encouraging results on the application of a new bio-NCP as a PTX carrier. We 
also propose new methodologies for the study of encapsulated drugs, based on state-of-the-art scattering tech-
niques combined with theoretical calculations. The next steps in this work will focus on further understanding 
the encapsulation effects on the dynamics of the released PTX and its correlation with its biological activity as well 
as in the optimization of the drug release mechanism.
Methods
Sample preparation. The detailed synthesis process for obtaining the bio-NCP is described elsewhere28. 
Briefly, from neutron diffraction results28, we determined that 0.41 mg of Fe per mg of nanoparticles were precip-
itated from a solution of salts, and subsequently encapsulated in chitosan by the double emulsion method. The 
chitosan was then cross-linked by reaction with glutaraldehyde and a final mimetization process was performed 
to modify the surface with apatite forming the bio-NCP nanocomposite. Depending on the mimetization effi-
ciency, which is not easily determined as it is connected to the amount of apatite effectively present in the polymer 
surface, in the final bio-NCP the amount of Fe per mg can vary between 0.20 mg (100% efficiency) to 0.27 mg 
(0% efficiency). The bio-NCP + PTX was produced by a similar method that included adding PTX to the solution 
before crosslinking of the chitosan. Therefore we can assume that the amount of Fe content is the bio-NCP + PTX 
is similar. Further details are given in the supplementary information.
In-vitro tests using human monocytes, HCT116 (colon cancer) and 3LL (lung cancer) cultures. 
Human monocytes were isolated from peripheral blood of healthy donors in accordance to the Declaration of 
Helsinki. All healthy volunteers provided informed consent. The study was approved by the Health Research 
Ethics Committee, Plataforma Brasil (http://aplicacao.saude.gov.br/plataformabrasil/login.jsf), with the decision 
number 1358038 and the CAAE number 50995715.9.0000.5411. Stable cancer cell lines, provided by Dr. Kaneno’s 
laboratory, were used. Thus no approval from the local ethical committee was required. The detailed processes 
involved on the preparation of cell cultures are described in the supplementary information. After preparation, 
the cells were set to 2 × 105 cells/mL and dispensed on rounded glass slides (∅ 13 mm), previously coated with 
poly-L-lysine. To promote the cell attachment on the slides, the cultures were kept for 2 h at 37 °C under 5% CO2.
In-vitro response of monocytes, HCT116 and 3LL cells to pure ferrite and bio-NCP nanoparticles. 
The glass slides were washed three times with warm complete culture medium (described in supplementary infor-
mation) (1 mL each time) and allowed to interact with 50 μg of either pure ferrite or bio-NCP nanoparticles. The 
cell cultures were kept for 2 h at 37 °C under 5% CO2 to allow direct contact between the cell surfaces and the nan-
oparticles. The slides were then washed with fresh phosphate buffered salt solution (PBS) at room temperature, 
the cell monolayers fixed with 2.5% glutaraldehyde and routinely processed to microscopy analysis as follows.
Morphological analysis by scanning electron microscopy. After fixation of the monolayers on the 
slides, the cells were dehydrated with ethanol solutions of 7.5, 15, 30, 50, 70, 90 and 100%, twice within 10 min 
www.nature.com/scientificreports/
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for each alcohol concentration, and submitted to supercritical drying (over the critical point) in a CO2 atmos-
phere for further metallization. The samples were subsequently analysed with scanning electron microscopy 
(SEM) (FEI, Quanta 200 equipped with an Oxford, Inca, 250P20 EDS) and 7 images (1000 × magnification) were 
randomly collected for each slide. The distributions of the cells aspect ratio were evaluated with the software 
ImagePro 4.1.0.0. No study was conducted for determining the number of cells; therefore the cell counts were 
normalized to the maximum value. EDS was used to map the Fe concentration over the cells. The nanoparticles 
amount, as well as the instrument parameters were set to provide the same signal/noise ratio for a same mass of 
either Mn-Zn ferrite or bio-NCP.
Cytotoxicity assays with Balb/c 3T3 fibroblasts. The toxicity of the pure ferrite, bio-NCP and 
bio-NCP  +  PTX was evaluated in respect to Balb/c 3T3 fibroblasts (clone A31–American Type Culture 
Collection) as follows. Firstly, the cells were processed as described in the supplementary information, dispensed 
in 96-well plates, each one containing 5 × 104 cells, and kept in culture for 24 h. Subsequently, 50 μg of each sam-
ple, i.e. pure ferrite, bio-NCP and bio-NCP  +  PTX, was suspended in the same culture media used to cultivate 
the cells and added to the plates allowing for their interaction with the cells. After 24 h, the supernatant, i.e. the 
excess of liquid and magnetic nanoparticles, was removed, the cells washed with PBS-A and subjected to incu-
bation with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) with 0.5 mg of MTT/mL of 
DMEM for 4 hours. This resulted in the formation of the formazan dye in the living cells, which was solubilized 
in DMSO and quantified using a microplate photometer by reading at 570 nm. The obtained absorbance values 
reflect the viability of the cells. The experiments were performed in duplicates with a n = 6 each.
Near edge X-ray absorption fine structure (NEXAFS) spectroscopy and Scanning Transmission 
X-ray Microscopy (STXM). PTX and bio-NCP samples were dispersed in ethanol for deposition onto sil-
icon nitride membranes (Silson, England) and placed in a low-vacuum environment for X-ray analysis using 
the carbon K-edge photon energy range (250 to 350 eV) at the PolLux beam-line (Swiss Light Source at the Paul 
Scherrer Institute, Switzerland)47–49. For the STXM experiments, a monochromatic X-ray beam is focused on the 
sample and the measured transmitted intensity is used to build a pixel-by-pixel image. When tuning the X-ray 
photon energy to resonance features present in the NEXAFS spectrum, the STXM images will display strong 
features that are related to the natural contrast based on the molecular bonding of the constituent materials. Thus 
by combining a set of images obtained at selected photon energies with the NEXAFS spectra of the component 
materials, the sample chemical composition map is calculated using singular value decomposition50. Therefore, 
after the NEXAFS spectra of the PTX and of the bio-NCP were collected, STXM images for the bio-NCP + PTX 
were obtained at X-ray energies of: 275 eV, 283 eV, 286 eV, 300 eV, 320 eV and 347 eV. The images and spectra were 
analysed using the aXis2000 software package51.
Inelastic neutron scattering (INS) and Density Functional Theory (DFT) calculations. The vibra-
tional dynamics of PTX, bio-NCP and bio-NCP + PTX were investigated by means of neutron spectroscopy 
using the FDS spectrometer at the Lujan Center of the Los Alamos National Laboratory (USA) at 10 K. By using 
this spectrometer it was possible to observe molecular motions between 50 and 500 cm−1. The samples were 
mounted in sealed aluminium containers and a vanadium run was used for correcting the data.
Structural optimization of the gas-phase paclitaxel molecule at 0 K and subsequent calculation of harmonic 
vibrational frequencies were carried out at the B3LYP/6-31 + G(d′ ) level of theory using Gaussian0952. The start-
ing atomic positions were taken from the crystal structure of 2-carbamate taxol, described in ref. 53. Frequencies 
and vibrational amplitudes from the Gaussian calculation were then used to calculate intensities and vibrational 
spectra of the inelastic neutron scattering spectra using the program a_climax54. The FTIR spectrum for the PTX 
was also calculated and used for mode assignment in the range from 1400 to 1900 cm−1.
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